Hims is three different businesses wearing one brand
Hims (and its sister brand Hers) sells across hair loss, erectile dysfunction, and, more recently, GLP-1 weight loss medication, plus smaller lines like topical skincare and mental health. These categories have almost nothing in common clinically.
Lumping them into one "is Hims good" verdict misses the point, since regulatory status, risk profile, and value proposition differ for each.
What ties them together is the delivery model: an online intake questionnaire reviewed by a licensed prescriber, with medication shipped directly, skipping the in-person doctor visit. That model is legal. It's mainstream across telehealth now. But it shifts more of the screening burden onto self-reported history than a traditional visit would.
Hair loss: finasteride and minoxidil, not a Hims invention
Hims's hair products are built on two decades-old, FDA-approved generics: oral finasteride (a 5-alpha-reductase inhibitor that lowers DHT, the hormone that miniaturizes hair follicles in male pattern baldness) and topical minoxidil (a vasodilator with a separately established, though less completely understood, hair growth effect).
Current pricing runs from around $15/month for minoxidil alone, up to $35/month or more for combination finasteride-plus-minoxidil formats, with topical finasteride spray options also in that range.
Both drugs have real randomized trial evidence behind them. Far more than most hair supplements on the market, including Hims's own sister products in that space. The gap between Hims and a dermatologist's prescription for the same drugs is convenience and price transparency, not medication quality, since it is the same generic compound either way.
The finasteride side effect question
Finasteride's FDA label lists sexual side effects, decreased libido, erectile dysfunction, and reduced ejaculate volume, in a minority of users. Most cases resolve after stopping the drug, though not every case does.
A smaller, more contested subset of reports describes these effects persisting after discontinuation, sometimes referred to as post-finasteride syndrome, a condition not formally recognized in FDA labeling but documented in case reports and patient advocacy in published literature.
Any finasteride prescription carries the same label, regardless of pharmacy or brand, so this risk isn't unique to Hims. What's actually worth debating is whether a brief online questionnaire adequately counsels patients on this risk compared to an in-person conversation with a dermatologist or urologist, where the conversation can be more thorough and individualized. That critique applies to direct-to-consumer telehealth generally, Hims included.
ED treatment: the same drugs as everyone else
Hims's ED line dispenses sildenafil and tadalafil, identical to Viagra and Cialis generics, through the same telehealth intake model used across the category. Nothing proprietary here.
The comparison to competitors like BlueChew and Roman comes down to pricing tiers, format (standard tablet for Hims versus chewable for BlueChew), and whether a given user is already cross-shopping Hims for hair or weight loss products, where bundling could matter.
The contraindications and side effect profile are the same as for any PDE5 inhibitor: nitrate interactions are the serious one, with headache, flushing and indigestion as the common, non-serious ones.
A full comparison of the economics and chewable-speed marketing claims specific to that category is in the BlueChew review.
GLP-1 weight loss: the most unsettled part of the business
This is where Hims has drawn the most regulatory scrutiny. For a period, Hims sold compounded semaglutide, a pharmacy-compounded version of the active ingredient in Ozempic and Wegovy, legally permitted while the branded drug was on the FDA's official shortage list.
Once Novo Nordisk's manufacturing caught up and the shortage exemption ended, that compounding pathway narrowed sharply. The practice drew public criticism, including from the FDA and from Novo Nordisk directly, over marketing practices and whether compounded doses were being accurately represented.
Following a March 2026 settlement with Novo Nordisk, Hims shifted to becoming an authorized distribution partner for branded Wegovy and Ozempic rather than continuing to rely on compounding. That change carries a real price jump: membership now starts around $39 for the first month, stepping up to $149/month, with the branded medication itself priced separately at roughly $249 to $399+/month depending on dose.
That's a significant increase over the compounded product's earlier pricing. Prices went up, full stop. Anyone evaluating Hims for GLP-1 treatment today is paying for a branded, FDA-approved drug through a legitimate distribution channel. Different deal entirely. More expensive too, compared to the compounded product Hims built its early weight loss business on.
Real subscription cost math
Hims's advertised "starting at" prices consistently reflect the lowest-dose, longest-commitment option. Standard across the telehealth category, but worth flagging explicitly. A realistic monthly range by category: hair loss roughly $15 to $60+, ED roughly $25 to $40+ depending on dose and quantity, and GLP-1 weight loss roughly $288 to $548+ once the membership fee and branded medication cost are combined.
None of these figures include insurance, which Hims's direct-pay model generally bypasses. Someone with insurance coverage for finasteride, minoxidil, or a GLP-1 medication through a traditional doctor and pharmacy may pay substantially less than the Hims direct-pay price, particularly for the GLP-1 category where insurance coverage, when available, can dramatically undercut the $249 to $399+/month cash price.
| Category | Typical monthly range | What it actually is |
|---|---|---|
| Hair loss | $15 to $60+ | Generic finasteride and/or minoxidil |
| ED treatment | $25 to $40+ | Generic sildenafil or tadalafil |
| GLP-1 weight loss | $288 to $548+ | Branded Wegovy/Ozempic plus membership fee |
Is Hims legit?
As a prescribing and dispensing operation, yes. Licensed prescribers, FDA-approved medications (now including branded GLP-1 drugs rather than compounded versions), and licensed pharmacy fulfillment. The brand's marketing tone, casual, lifestyle-forward, optimized for social media, is a separate question from the clinical legitimacy of what's actually being prescribed.
The more useful question for a prospective customer is whether the convenience premium and telehealth-only counseling model fit their situation, particularly for finasteride given the persistent side effect question, and whether the newly repriced GLP-1 line still makes financial sense compared to pursuing insurance coverage or a local prescriber first.
Who it makes sense for
Hims is a reasonable fit for someone without easy access to a dermatologist or primary care provider, who wants a fast, private path to a well-established generic medication for hair loss or ED, and who is comfortable with asynchronous online prescribing.
It's a weaker fit for anyone with a complex medical history that benefits from in-person evaluation. Also weaker for anyone eyeing the weight loss line purely on cost, since current branded-drug pricing is high enough that checking insurance coverage first is worth the extra step.
